Researcher Next
Create account
← Back to directory

Ofri Mosenzon

Researcher Next ID · RN-011049

Researcher · Medicine

Alzheimer's Association of Israel

, Israel

Sign in to saveSign in to claim
Not currently recruitingFunding unknown
Works count
264
Citation count
27,500
H-index
56
i10-index
118

Research interests

Medicine
Biochemistry, Genetics and Molecular Biology
Diabetes Treatment and Management
Metabolism, Diabetes, and Cancer
Diabetes Management and Research
Chronic Kidney Disease and Diabetes
Pancreatic function and diabetes

Publications

  • Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    New England Journal of Medicine · 2019 · 10.1056/nejmoa1901118

  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    New England Journal of Medicine · 2018 · 10.1056/nejmoa1812389

  • SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

    The Lancet · 2018 · 10.1016/s0140-6736(18)32590-x

  • Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

    The Lancet · 2018 · 10.1016/s0140-6736(18)31773-2

  • Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

    New England Journal of Medicine · 2013 · 10.1056/nejmoa1307684

Current projects

    No projects listed.